

IQVIA Asset Intelligence Solutions Enable Evidence-Based Decision Making

Predict technical, regulatory and clinical trial success to discover promising assets and understand the competitive clinical development landscape

Pharma development's competitive advantage

IQVIA's Asset Intelligence Solutions uniquely leverage clinical pipeline data and advanced artificial intelligence/machine learning — coupled with domain expertise — allowing you to identify promising assets with high probability of technical and regulatory success and gain a deep understanding of the clinical development competitive landscape for evidence-based decision-making.



"We are extremely impressed with the speed and quality of the output. We didn't expect to see so much detail in such a short amount of time."

- Head of Global Pricing and Analytics

Power your clinical investment decisions with AI/ML

Using advanced AI/ML methodologies, combined with IQVIA's world-class data scientists and domain expertise via a consultative approach, IQVIA's Asset Intelligence Solutions provides:



Competitive Landscapes

Gain a deep understanding of the clinical development landscape quickly and objectively



Objective Assessments

Identify assets with a high probability of success and their time to approval to optimize investment decisions



Actionable Insights

Drive decision-making regarding assets to pursue and potential areas for therapeutic expansion

Get accurate predictions and competitive insights faster

IQVIA uses leading industry datasets, applying our AI/ML capabilities and coupling it with our data science & domain subject matter expertise (SME) to deliver Asset Intelligence Solutions. This Connected Intelligence approach yields Probability of Technical and Regulatory Success (PTRS) scores for specific clinical development pathways and competitive clinical development landscape insights.

INDUSTRY TRUSTED DATA SOURCES

- Data containing clinical trials and regulatory decisions is pulled from a variety of trusted sources
- >50,000 drug development pathways dating from 2008 and on are used

APPLICATION OF ADVANCED AI/ML METHODOLOGIES

- A unique combination of advanced AI/ML methodologies are applied. First, data from different sources is harmonized to provide a holistic view of a clinical development pathway — providing baseline success rates of clinical development pathways aggregated by indication, phase, target, modality, etc.

PTRS & TIME TO APPROVAL

- Holistic views of clinical development pathways are integrated into the AI/ML modeling to allow for predicting of the probability of technical & regulatory success (PTRS) and to ascertain prediction drivers. For pathways predicted to succeed, a time to approval can also be estimated.

These PTRS scores and competitive insights can identify promising assets within your company's established therapy area or for therapy area expansion. Asset Intelligence Solutions provides you confidence in assessing opportunities and insights to drive competitive advantage.

Asset Intelligence Solutions use a consultative approach that is customized to meet your specific needs. Examples of what we can provide as part of your custom deliverable include:

- Comprehensive search of the entire clinical pipeline database by intervention, indication and NCT-ID — eliminating the need to rifle through multiple sources allowing for quick and objective assessment of potential assets.
- Ability to focus the analysis and provide results based on intervention, indication, target, sponsors, development phase, status (in development, abandoned, approved), start and/or end date of latest clinical trial — allowing you to quickly get to the information you need for decision-making.

- Baseline PTRS calculation of all interventions for a specific indication allowing for quick comparison and supporting strategic decision-making on drug assets.
- A complete list of assets can be generated for a given pathway that includes intervention, indication, target, development phase, sponsors and PTRS — minimizing the overall resources and costs required for investment efforts.
- AI/ML-based calculation of PTRS with detailed prediction drivers for context, such as trial geography, historical success of similar drugs, and clinical trial design variable — helping you understand potential risks involved with investments or clinical program decisions.

Quickly and confidently understand the probability of an asset's technical success and its likelihood of attaining regulatory approval, while reducing time and using less resources.